Performance evaluation of the MAGLUMI Hepatitis B virus surface antigen chemiluminescence immunoassay

A highly sensitive and reliable Hepatitis B virus surface antigen (HBsAg) measurement is essential to universal screening, timely diagnosis, and management of Hepatitis B virus (HBV) infection. This study aimed to evaluate the performance of MAGLUMI HBsAg chemiluminescence immunoassay (CLIA). MAGLUM...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of medical virology Ročník 96; číslo 7; s. e29817 - n/a
Hlavní autori: Shen, Lihong, Zhang, Yun, Shi, Min, Shao, Lijia, Feng, Shengchun, Li, Weiting, Fang, Zhonggang, Yin, Jun, Li, Tinghua
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Wiley Subscription Services, Inc 01.07.2024
Predmet:
ISSN:0146-6615, 1096-9071, 1096-9071
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract A highly sensitive and reliable Hepatitis B virus surface antigen (HBsAg) measurement is essential to universal screening, timely diagnosis, and management of Hepatitis B virus (HBV) infection. This study aimed to evaluate the performance of MAGLUMI HBsAg chemiluminescence immunoassay (CLIA). MAGLUMI HBsAg (CLIA) was compared against ARCHITECT HBsAg. 411 HBsAg positive samples, including different stages of infection, genotypes, subtypes, mutants, and 30 seroconversion panels were tested to evaluate diagnostic sensitivity. Diagnostic specificity was evaluated by testing 205 hospitalized samples and 5101 blood donor samples. Precision, limit of blank (LoB), limit of detection (LoD), and linearity were also verified. The diagnostic sensitivity of the MAGLUMI HBsAg (CLIA) was 100% with better seroconversion sensitivity than ARCHITECT HBsAg. The MAGLUMI HBsAg (CLIA) has optimal detection efficacy for HBV subgenotypes samples. The analytical sensitivity is 0.039 IU/mL. The initial diagnostic specificity is 99.63% on blood donors and 96.59% on hospitalized samples. The verification data demonstrated high repeatability, a LoB of 0.02 IU/mL, LoD of 0.05 IU/mL and an excellent linearity of 0.050–250 IU/mL (R2 = 0.9946). The MAGLUMI HBsAg (CLIA) is proved a highly sensitive and reliable assay with optimal subgenotype detection efficacy.
AbstractList A highly sensitive and reliable Hepatitis B virus surface antigen (HBsAg) measurement is essential to universal screening, timely diagnosis, and management of Hepatitis B virus (HBV) infection. This study aimed to evaluate the performance of MAGLUMI HBsAg chemiluminescence immunoassay (CLIA). MAGLUMI HBsAg (CLIA) was compared against ARCHITECT HBsAg. 411 HBsAg positive samples, including different stages of infection, genotypes, subtypes, mutants, and 30 seroconversion panels were tested to evaluate diagnostic sensitivity. Diagnostic specificity was evaluated by testing 205 hospitalized samples and 5101 blood donor samples. Precision, limit of blank (LoB), limit of detection (LoD), and linearity were also verified. The diagnostic sensitivity of the MAGLUMI HBsAg (CLIA) was 100% with better seroconversion sensitivity than ARCHITECT HBsAg. The MAGLUMI HBsAg (CLIA) has optimal detection efficacy for HBV subgenotypes samples. The analytical sensitivity is 0.039 IU/mL. The initial diagnostic specificity is 99.63% on blood donors and 96.59% on hospitalized samples. The verification data demonstrated high repeatability, a LoB of 0.02 IU/mL, LoD of 0.05 IU/mL and an excellent linearity of 0.050–250 IU/mL (R2 = 0.9946). The MAGLUMI HBsAg (CLIA) is proved a highly sensitive and reliable assay with optimal subgenotype detection efficacy.
A highly sensitive and reliable Hepatitis B virus surface antigen (HBsAg) measurement is essential to universal screening, timely diagnosis, and management of Hepatitis B virus (HBV) infection. This study aimed to evaluate the performance of MAGLUMI HBsAg chemiluminescence immunoassay (CLIA). MAGLUMI HBsAg (CLIA) was compared against ARCHITECT HBsAg. 411 HBsAg positive samples, including different stages of infection, genotypes, subtypes, mutants, and 30 seroconversion panels were tested to evaluate diagnostic sensitivity. Diagnostic specificity was evaluated by testing 205 hospitalized samples and 5101 blood donor samples. Precision, limit of blank (LoB), limit of detection (LoD), and linearity were also verified. The diagnostic sensitivity of the MAGLUMI HBsAg (CLIA) was 100% with better seroconversion sensitivity than ARCHITECT HBsAg. The MAGLUMI HBsAg (CLIA) has optimal detection efficacy for HBV subgenotypes samples. The analytical sensitivity is 0.039 IU/mL. The initial diagnostic specificity is 99.63% on blood donors and 96.59% on hospitalized samples. The verification data demonstrated high repeatability, a LoB of 0.02 IU/mL, LoD of 0.05 IU/mL and an excellent linearity of 0.050-250 IU/mL (R  = 0.9946). The MAGLUMI HBsAg (CLIA) is proved a highly sensitive and reliable assay with optimal subgenotype detection efficacy.
A highly sensitive and reliable Hepatitis B virus surface antigen (HBsAg) measurement is essential to universal screening, timely diagnosis, and management of Hepatitis B virus (HBV) infection. This study aimed to evaluate the performance of MAGLUMI HBsAg chemiluminescence immunoassay (CLIA). MAGLUMI HBsAg (CLIA) was compared against ARCHITECT HBsAg. 411 HBsAg positive samples, including different stages of infection, genotypes, subtypes, mutants, and 30 seroconversion panels were tested to evaluate diagnostic sensitivity. Diagnostic specificity was evaluated by testing 205 hospitalized samples and 5101 blood donor samples. Precision, limit of blank (LoB), limit of detection (LoD), and linearity were also verified. The diagnostic sensitivity of the MAGLUMI HBsAg (CLIA) was 100% with better seroconversion sensitivity than ARCHITECT HBsAg. The MAGLUMI HBsAg (CLIA) has optimal detection efficacy for HBV subgenotypes samples. The analytical sensitivity is 0.039 IU/mL. The initial diagnostic specificity is 99.63% on blood donors and 96.59% on hospitalized samples. The verification data demonstrated high repeatability, a LoB of 0.02 IU/mL, LoD of 0.05 IU/mL and an excellent linearity of 0.050-250 IU/mL (R2 = 0.9946). The MAGLUMI HBsAg (CLIA) is proved a highly sensitive and reliable assay with optimal subgenotype detection efficacy.A highly sensitive and reliable Hepatitis B virus surface antigen (HBsAg) measurement is essential to universal screening, timely diagnosis, and management of Hepatitis B virus (HBV) infection. This study aimed to evaluate the performance of MAGLUMI HBsAg chemiluminescence immunoassay (CLIA). MAGLUMI HBsAg (CLIA) was compared against ARCHITECT HBsAg. 411 HBsAg positive samples, including different stages of infection, genotypes, subtypes, mutants, and 30 seroconversion panels were tested to evaluate diagnostic sensitivity. Diagnostic specificity was evaluated by testing 205 hospitalized samples and 5101 blood donor samples. Precision, limit of blank (LoB), limit of detection (LoD), and linearity were also verified. The diagnostic sensitivity of the MAGLUMI HBsAg (CLIA) was 100% with better seroconversion sensitivity than ARCHITECT HBsAg. The MAGLUMI HBsAg (CLIA) has optimal detection efficacy for HBV subgenotypes samples. The analytical sensitivity is 0.039 IU/mL. The initial diagnostic specificity is 99.63% on blood donors and 96.59% on hospitalized samples. The verification data demonstrated high repeatability, a LoB of 0.02 IU/mL, LoD of 0.05 IU/mL and an excellent linearity of 0.050-250 IU/mL (R2 = 0.9946). The MAGLUMI HBsAg (CLIA) is proved a highly sensitive and reliable assay with optimal subgenotype detection efficacy.
A highly sensitive and reliable Hepatitis B virus surface antigen (HBsAg) measurement is essential to universal screening, timely diagnosis, and management of Hepatitis B virus (HBV) infection. This study aimed to evaluate the performance of MAGLUMI HBsAg chemiluminescence immunoassay (CLIA). MAGLUMI HBsAg (CLIA) was compared against ARCHITECT HBsAg. 411 HBsAg positive samples, including different stages of infection, genotypes, subtypes, mutants, and 30 seroconversion panels were tested to evaluate diagnostic sensitivity. Diagnostic specificity was evaluated by testing 205 hospitalized samples and 5101 blood donor samples. Precision, limit of blank (LoB), limit of detection (LoD), and linearity were also verified. The diagnostic sensitivity of the MAGLUMI HBsAg (CLIA) was 100% with better seroconversion sensitivity than ARCHITECT HBsAg. The MAGLUMI HBsAg (CLIA) has optimal detection efficacy for HBV subgenotypes samples. The analytical sensitivity is 0.039 IU/mL. The initial diagnostic specificity is 99.63% on blood donors and 96.59% on hospitalized samples. The verification data demonstrated high repeatability, a LoB of 0.02 IU/mL, LoD of 0.05 IU/mL and an excellent linearity of 0.050–250 IU/mL ( R 2  = 0.9946). The MAGLUMI HBsAg (CLIA) is proved a highly sensitive and reliable assay with optimal subgenotype detection efficacy.
Author Shao, Lijia
Yin, Jun
Li, Tinghua
Shi, Min
Shen, Lihong
Feng, Shengchun
Li, Weiting
Fang, Zhonggang
Zhang, Yun
Author_xml – sequence: 1
  givenname: Lihong
  surname: Shen
  fullname: Shen, Lihong
  organization: Zhejiang University School of Medicine
– sequence: 2
  givenname: Yun
  surname: Zhang
  fullname: Zhang, Yun
  organization: Shenzhen New Industries Biomedical Engineering Co. Ltd
– sequence: 3
  givenname: Min
  surname: Shi
  fullname: Shi, Min
  organization: Shenzhen New Industries Biomedical Engineering Co. Ltd
– sequence: 4
  givenname: Lijia
  surname: Shao
  fullname: Shao, Lijia
  organization: Zhejiang University School of Medicine
– sequence: 5
  givenname: Shengchun
  surname: Feng
  fullname: Feng, Shengchun
  organization: Zhejiang University School of Medicine
– sequence: 6
  givenname: Weiting
  surname: Li
  fullname: Li, Weiting
  organization: Shenzhen New Industries Biomedical Engineering Co. Ltd
– sequence: 7
  givenname: Zhonggang
  surname: Fang
  fullname: Fang, Zhonggang
  organization: Shenzhen New Industries Biomedical Engineering Co. Ltd
– sequence: 8
  givenname: Jun
  surname: Yin
  fullname: Yin, Jun
  organization: Shenzhen New Industries Biomedical Engineering Co. Ltd
– sequence: 9
  givenname: Tinghua
  orcidid: 0009-0005-2334-2139
  surname: Li
  fullname: Li, Tinghua
  email: litinghua@snibe.cn
  organization: Shenzhen New Industries Biomedical Engineering Co. Ltd
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39034740$$D View this record in MEDLINE/PubMed
BookMark eNp1kU9vEzEUxC1URNPCgS-ALHGBw7bP9v7xHktV2qJEcGh7tWznLXW0toO9myrfnk2TXio4PenpN6PRzAk5CjEgIR8ZnDEAfr7ymzPeSta8ITMGbV200LAjMgNW1kVds-qYnOS8AgDZcv6OHIsWRNmUMCP4C1MXk9fBIsWN7kc9uBho7OjwiHRxcT2_X9zSG1xP_8Fl-o1uXBozzWPq9KTRYXC_MVD7iN71o3cBs8Wdm_N-DFHnrLfvydtO9xk_HO4puf9-dXd5U8x_Xt9eXswLKyrRFLwBMKUQKGxlq1Z01krTGM0bIw2vNOeMG6mXumqxakBDV9aslXJZGim72ohT8mXvu07xz4h5UN5NafpeB4xjVgKk4Kxikk_o51foKo4pTOl2VMUBSlZO1KcDNRqPS7VOzuu0VS8FTsD5HrAp5pywU9YNzxUOSbteMVC7idQ0kXqeaFJ8faV4Mf0Xe3B_cj1u_w-qH4uHveIvNQyfqw
CitedBy_id crossref_primary_10_1016_j_trac_2024_117985
Cites_doi 10.3748/wjg.v20.i30.10395
10.3201/eid1203.050038
10.4254/wjh.v6.i12.860
10.1016/S0140-6736(22)01468-4
10.1016/j.jhep.2019.03.034
10.25259/GJMPBU_77_2022
10.1038/s41598-019-56015-8
10.1111/hepr.13602
10.1128/jcm.02204-21
10.1007/978-3-030-03502-0_9
10.1002/hep.22881
10.7150/ijbs.55724
10.1001/jamanetworkopen.2022.16485
10.1007/s005350300043
10.15585/mmwr.rr7201a1
10.1002/hep.29800
10.3748/wjg.v24.i31.3488
10.1016/j.jhep.2011.06.006
10.1016/j.gastha.2023.01.017
10.1016/j.lanwpc.2022.100428
10.1371/journal.pone.0272920
10.1002/hep.31991
10.1016/S2468-1253(22)00201-1
10.3748/wjg.15.3099
10.1016/j.clinre.2023.102180
10.1002/hep.21347
10.3390/genes9100495
10.4254/wjh.v7.i27.2729
10.1016/j.jcv.2020.104507
10.3389/fmicb.2021.678537
10.1038/s41575-023-00760-9
10.3390/v13061124
10.3390/v14071504
10.1016/j.jcv.2013.06.011
10.1016/S1473-3099(16)30204-3
10.1016/j.heliyon.2019.e02556
ContentType Journal Article
Copyright 2024 Wiley Periodicals LLC.
Copyright_xml – notice: 2024 Wiley Periodicals LLC.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7TK
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
DOI 10.1002/jmv.29817
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Virology and AIDS Abstracts
Technology Research Database
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
CrossRef
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1096-9071
EndPage n/a
ExternalDocumentID 39034740
10_1002_jmv_29817
JMV29817
Genre researchArticle
Research Support, Non-U.S. Gov't
Evaluation Study
Journal Article
GrantInformation_xml – fundername: Jinhua Science and Technology Bureau
  funderid: 2021‐4‐009
– fundername: Jinhua Central Hospital
  funderid: JY2021‐1‐04
– fundername: Jinhua Central Hospital
  grantid: JY2021-1-04
– fundername: Jinhua Science and Technology Bureau
  grantid: 2021-4-009
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3O-
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AI.
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
ECGQY
EJD
ELTNK
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGB
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V2E
VH1
W8V
W99
WBKPD
WHG
WIB
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XPP
XV2
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
AIQQE
CITATION
O8X
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7TK
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
ID FETCH-LOGICAL-c3537-2700b433e3c5c593fcc8b7ba27b8b25a2212b8ada59e570a0f461988d4b88f6b3
IEDL.DBID DRFUL
ISICitedReferencesCount 1
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001279358500021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0146-6615
1096-9071
IngestDate Fri Jul 11 15:33:54 EDT 2025
Sat Nov 29 14:43:08 EST 2025
Wed Sep 24 03:03:57 EDT 2025
Tue Nov 18 22:23:15 EST 2025
Sat Nov 29 03:41:01 EST 2025
Wed Jan 22 17:18:02 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords performance evaluation
Hepatitis B virus surface antigen
Hepatitis B virus surface antigen sensitivity
Hepatitis B virus surface antigen subgenotypes
MAGLUMI
immunoassay
Language English
License 2024 Wiley Periodicals LLC.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3537-2700b433e3c5c593fcc8b7ba27b8b25a2212b8ada59e570a0f461988d4b88f6b3
Notes Lihong Shen, Yun Zhang, and Min Shi contributed equally to this work and share first authorship.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0009-0005-2334-2139
PMID 39034740
PQID 3085200414
PQPubID 105515
PageCount 11
ParticipantIDs proquest_miscellaneous_3083215182
proquest_journals_3085200414
pubmed_primary_39034740
crossref_citationtrail_10_1002_jmv_29817
crossref_primary_10_1002_jmv_29817
wiley_primary_10_1002_jmv_29817_JMV29817
PublicationCentury 2000
PublicationDate July 2024
2024-07-00
20240701
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: July 2024
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: London
PublicationTitle Journal of medical virology
PublicationTitleAlternate J Med Virol
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2019; 9
2019; 71
2019; 5
2015; 3
2006; 12
2023; 18
2023; 401
2011; 55
2003; 38
2020; 129
2023; 2
2022; 22
2018; 67
2021; 74
2016; 16
2015; 7
2021; 51
2009; 49
2018; 24
2014; 20
2023; 20
2021; 13
2018; 9
2013; 58
2023; 47
2021; 12
2022; 60
2022; 5
2006; 44
2022; 7
2021; 17
2022; 14
2014; 6
2019; 177
2023; 72
2009; 15
2022; 17
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_40_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_39_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_38_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_37_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_36_1
e_1_2_10_12_1
e_1_2_10_35_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_34_1
e_1_2_10_10_1
e_1_2_10_33_1
e_1_2_10_11_1
e_1_2_10_31_1
e_1_2_10_30_1
Gonzalez J (e_1_2_10_32_1) 2015; 3
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 20
  start-page: 524
  year: 2023
  end-page: 537
  article-title: Global burden of hepatitis B virus: current status, missed opportunities and a call for action
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 17
  year: 2022
  article-title: Global epidemiology of occult hepatitis B virus infections in blood donors, a systematic review and meta‐analysis
  publication-title: PLoS One
– volume: 55
  start-page: 1121
  year: 2011
  end-page: 1131
  article-title: Hepatitis B surface antigen quantification: why and how to use it in 2011—a core group report
  publication-title: J Hepatol
– volume: 5
  year: 2019
  article-title: A systematic genotype and subgenotype re‐ranking of hepatitis B virus under a novel classification standard
  publication-title: Heliyon
– volume: 38
  start-page: 244
  year: 2003
  end-page: 253
  article-title: Molecular analysis of antigenicity and immunogenicity of a vaccine‐induced escape mutant of hepatitis B virus
  publication-title: J Gastroenterol
– volume: 3
  start-page: 63
  year: 2015
  end-page: 69
  article-title: Diagnosis and management of occult, hepatitis B virus infection: a short revive
  publication-title: Hepatology
– volume: 177
  start-page: 231
  year: 2019
  end-page: 250
  article-title: HIV‐HBV and HIV‐HCV coinfection and liver cancer development
  publication-title: Cancer Treat Res
– volume: 24
  start-page: 3488
  year: 2018
  end-page: 3499
  article-title: Hepatitis B virus infection: defective surface antigen expression and pathogenesis
  publication-title: World J Gastroenterol
– volume: 58
  start-page: 47
  year: 2013
  end-page: 53
  article-title: Performance of hepatitis B surface antigen tests with the first WHO international hepatitis B virus genotype reference panel
  publication-title: J Clin Virol
– volume: 60
  year: 2022
  article-title: Detection of the hepatitis B surface antigen in patients with occult hepatitis B by use of an assay with enhanced sensitivity
  publication-title: J Clin Microbiol
– volume: 14
  year: 2022
  article-title: Occult hepatitis B virus infection: an update
  publication-title: Viruses
– volume: 6
  start-page: 860
  year: 2014
  end-page: 869
  article-title: Occult hepatitis B virus infection
  publication-title: World J Hepatol
– volume: 129
  year: 2020
  article-title: The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection
  publication-title: J Clin Virol
– volume: 20
  start-page: 10395
  year: 2014
  end-page: 10404
  article-title: Natural history of chronic hepatitis B: phases in a complex relationship
  publication-title: World J Gastroenterol
– volume: 44
  start-page: 521
  year: 2006
  end-page: 526
  article-title: Global challenges in liver disease
  publication-title: Hepatology
– volume: 401
  start-page: 1039
  year: 2023
  end-page: 1052
  article-title: Hepatitis B
  publication-title: The Lancet
– volume: 9
  year: 2018
  article-title: The global hepatitis B virus genotype distribution approximated from available genotyping data
  publication-title: Genes
– volume: 2
  start-page: 467
  year: 2023
  end-page: 474
  article-title: The coexistence of hepatitis B surface antigen and anti‐HBs in patients with chronic HBV infection: prevalence and related factors
  publication-title: Gastro Hep Advances
– volume: 49
  start-page: S13
  year: 2009
  end-page: S21
  article-title: Hepatitis B: the virus and disease
  publication-title: Hepatology
– volume: 12
  start-page: 198
  year: 2006
  end-page: 203
  article-title: Detecting hepatitis B surface antigen mutants
  publication-title: Emerging Infect Dis
– volume: 5
  year: 2022
  article-title: Association of coexistent hepatitis B surface antigen and antibody with severe liver fibrosis and cirrhosis in treatment‐naive patients with chronic hepatitis B
  publication-title: JAMA Netw. Open
– volume: 15
  start-page: 3099
  year: 2009
  end-page: 3105
  article-title: Molecular characteristics and stages of chronic hepatitis B virus infection
  publication-title: World J Gastroenterol
– volume: 13
  year: 2021
  article-title: Envelope proteins of hepatitis B virus: molecular biology and involvement in carcinogenesis
  publication-title: Viruses
– volume: 67
  start-page: 1560
  year: 2018
  end-page: 1599
  article-title: Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
  publication-title: Hepatology
– volume: 18
  start-page: 1
  year: 2023
  article-title: Enzyme‐linked immunosorbent assay versus chemiluminescent immunoassay: a general overview
  publication-title: Glob J Med Pharm Biomed Update
– volume: 17
  start-page: 1125
  year: 2021
  end-page: 1137
  article-title: Paradoxical HBsAg and anti‐HBs coexistence among chronic HBV infections: causes and consequences
  publication-title: Int J Biol Sci
– volume: 74
  start-page: 2353
  year: 2021
  end-page: 2365
  article-title: Prevalence of HBV infection, vaccine‐Induced immunity, and susceptibility among at‐risk populations: US households, 2013‐2018
  publication-title: Hepatology
– volume: 7
  start-page: 932
  year: 2022
  end-page: 942
  article-title: Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta‐analysis
  publication-title: Lancet Gastroenterol Hepatol
– volume: 47
  year: 2023
  article-title: A review of epidemiology and clinical relevance of hepatitis B virus genotypes and subgenotypes
  publication-title: Clin. Res. Hepatol. Gastroenterol
– volume: 72
  start-page: 1
  year: 2023
  end-page: 25
  article-title: Screening and testing for hepatitis B virus infection: CDC recommendations—United States, 2023
  publication-title: MMWR Recomm Rep
– volume: 71
  start-page: 397
  year: 2019
  end-page: 408
  article-title: Update of the statements on biology and clinical impact of occult hepatitis B virus infection
  publication-title: J Hepatol
– volume: 22
  year: 2022
  article-title: Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: A simulation study
  publication-title: The Lancet Regional Health Western Pacific
– volume: 16
  start-page: 1399
  year: 2016
  end-page: 1408
  article-title: Requirements for global elimination of hepatitis B: a modelling study
  publication-title: Lancet Infect Dis
– volume: 9
  year: 2019
  article-title: Long‐term outcomes of HBsAg/anti‐HBs double‐positive versus HBsAg single‐positive patients with chronic hepatitis B
  publication-title: Sci Rep
– volume: 51
  start-page: 426
  year: 2021
  end-page: 435
  article-title: Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance
  publication-title: Hepatol Res
– volume: 12
  year: 2021
  article-title: Persistence of hepatitis B virus infection: a multi‐faceted player for hepatocarcinogenesis
  publication-title: Front Microbiol
– volume: 7
  start-page: 2729
  year: 2015
  end-page: 2739
  article-title: Clinical significance of hepatitis B surface antigen mutants
  publication-title: World J Hepatol
– ident: e_1_2_10_16_1
  doi: 10.3748/wjg.v20.i30.10395
– ident: e_1_2_10_25_1
  doi: 10.3201/eid1203.050038
– ident: e_1_2_10_31_1
  doi: 10.4254/wjh.v6.i12.860
– ident: e_1_2_10_5_1
  doi: 10.1016/S0140-6736(22)01468-4
– ident: e_1_2_10_28_1
  doi: 10.1016/j.jhep.2019.03.034
– ident: e_1_2_10_40_1
  doi: 10.25259/GJMPBU_77_2022
– ident: e_1_2_10_17_1
  doi: 10.1038/s41598-019-56015-8
– ident: e_1_2_10_35_1
  doi: 10.1111/hepr.13602
– ident: e_1_2_10_36_1
  doi: 10.1128/jcm.02204-21
– ident: e_1_2_10_39_1
  doi: 10.1007/978-3-030-03502-0_9
– ident: e_1_2_10_13_1
  doi: 10.1002/hep.22881
– ident: e_1_2_10_12_1
  doi: 10.7150/ijbs.55724
– ident: e_1_2_10_18_1
  doi: 10.1001/jamanetworkopen.2022.16485
– ident: e_1_2_10_26_1
  doi: 10.1007/s005350300043
– ident: e_1_2_10_8_1
  doi: 10.15585/mmwr.rr7201a1
– ident: e_1_2_10_10_1
  doi: 10.1002/hep.29800
– ident: e_1_2_10_11_1
  doi: 10.3748/wjg.v24.i31.3488
– ident: e_1_2_10_20_1
  doi: 10.1016/j.jhep.2011.06.006
– ident: e_1_2_10_19_1
  doi: 10.1016/j.gastha.2023.01.017
– ident: e_1_2_10_2_1
  doi: 10.1016/j.lanwpc.2022.100428
– ident: e_1_2_10_33_1
  doi: 10.1371/journal.pone.0272920
– ident: e_1_2_10_4_1
  doi: 10.1002/hep.31991
– ident: e_1_2_10_30_1
  doi: 10.1016/S2468-1253(22)00201-1
– ident: e_1_2_10_15_1
  doi: 10.3748/wjg.15.3099
– ident: e_1_2_10_24_1
  doi: 10.1016/j.clinre.2023.102180
– ident: e_1_2_10_38_1
  doi: 10.1002/hep.21347
– ident: e_1_2_10_22_1
  doi: 10.3390/genes9100495
– ident: e_1_2_10_37_1
– ident: e_1_2_10_27_1
  doi: 10.4254/wjh.v7.i27.2729
– volume: 3
  start-page: 63
  year: 2015
  ident: e_1_2_10_32_1
  article-title: Diagnosis and management of occult, hepatitis B virus infection: a short revive
  publication-title: Hepatology
– ident: e_1_2_10_34_1
  doi: 10.1016/j.jcv.2020.104507
– ident: e_1_2_10_6_1
– ident: e_1_2_10_14_1
  doi: 10.3389/fmicb.2021.678537
– ident: e_1_2_10_3_1
  doi: 10.1038/s41575-023-00760-9
– ident: e_1_2_10_9_1
  doi: 10.3390/v13061124
– ident: e_1_2_10_29_1
  doi: 10.3390/v14071504
– ident: e_1_2_10_21_1
  doi: 10.1016/j.jcv.2013.06.011
– ident: e_1_2_10_7_1
  doi: 10.1016/S1473-3099(16)30204-3
– ident: e_1_2_10_23_1
  doi: 10.1016/j.heliyon.2019.e02556
SSID ssj0008922
Score 2.4285014
Snippet A highly sensitive and reliable Hepatitis B virus surface antigen (HBsAg) measurement is essential to universal screening, timely diagnosis, and management of...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e29817
SubjectTerms Adolescent
Adult
Aged
Antigens
Blood
Blood donors
Chemiluminescence
Diagnostic systems
Effectiveness
Female
Genotype
Genotypes
Hepatitis
Hepatitis B
Hepatitis B - blood
Hepatitis B - diagnosis
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Hepatitis B Surface Antigens - immunology
Hepatitis B virus - genetics
Hepatitis B virus - immunology
Hepatitis B virus - isolation & purification
Hepatitis B virus surface antigen
Hepatitis B virus surface antigen sensitivity
Hepatitis B virus surface antigen subgenotypes
Humans
Immunoassay
Immunoassay - methods
Immunoassay - standards
Linearity
Luminescent Measurements - methods
MAGLUMI
Male
Middle Aged
Performance evaluation
Reproducibility of Results
Sensitivity analysis
Sensitivity and Specificity
Seroconversion
Viruses
Young Adult
Title Performance evaluation of the MAGLUMI Hepatitis B virus surface antigen chemiluminescence immunoassay
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.29817
https://www.ncbi.nlm.nih.gov/pubmed/39034740
https://www.proquest.com/docview/3085200414
https://www.proquest.com/docview/3083215182
Volume 96
WOSCitedRecordID wos001279358500021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1096-9071
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0008922
  issn: 0146-6615
  databaseCode: DRFUL
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3PT9swFH6CgqZd2MbGKGPIoB12yZracW1rp27QsalFaFpRb5Ht2FIRtKhpK_Hf85ykqdCGNIlbpDzLlt-vL_F7nwE-ZZnPuA-tW8qIKOlIHZmYu4h2jG_7DFNiUfJ_1RcXF3I0Upcb8HXVC1PyQ9Q_3IJnFPE6OLg2eWtNGnp9u_xClWyLTdiiaLdJA7ZOf_eG_ToQS1UeImAwiDAN8RWxUExb9eDH6egvjPkYshY5p_fqWat9DTsV1CTd0jbewIab7MKLQXWY_hbc5bppgKxZv8nUE0SFZND90R8OfpJzF4qu5-OcfCPL8WyRk3wx8xrHoFIClyexgXQAg1yooLchUpBx6DqZIi7X9-9g2Dv78_08qm5diCzjTIQGtdgkjDlmueWKeWulEUZTYaShXFNMdkbqTHPluIh17BP8CJMyS4yUvmPYHjQm04nbB-Ksy4Tg1slMJah6qTX6vNXWOOo6XDXh82rzU1tRkoebMW7SkkyZprhtabFtTTipRe9KHo5_CR2uNJhWrpinDEFlCAXtpAnH9Wt0onAyoiduuihkWMA-kjbhfan5eham0LZEEuNiCwU_PX36a3BVPBz8v-gHeEkRJpUFwIfQmM8W7iNs2yWqdXYEm2Ikjyq7fgDhK_tc
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB6VFAEX3pRAAYM4cNl240dsS1zKI6SwG1WoqXpb2V5bCmqTKmki9d93vLvZqAIkJG4reSxbHs_Mt_bMZ4D3ZRlKEWLplrYy4X1lEpsKn9C-Db1QYkisUv5PMjkaqdNTfbQFH9e1MDU_RHvgFi2j8tfRwOOB9P6GNfTX-WqPatWTt2Cb4zYSHdj-8nMwzlpPrHR9i4DeIME4JNbMQindbzvfjEe_gcybmLUKOoMH_zfdh3C_AZvkoN4dj2DLTx_Dnby5Tn8C_mhTNkA2vN9kFgjiQpIffMvG-SEZ-ph2fTlZkE9kNZkvF2SxnAeDfVAtkc2TuEg7gG4u5tC76CvIJNadzBCZm6unMB58Pf48TJp3FxLHBJOxRC21nDHPnHBCs-CcstIaKq2yVBiK4c4qUxqhvZCpSQPH3zClSm6VCn3LnkFnOpv650C886WUwnlVao7KV8ag1TvjrKe-L3QXPqxXv3ANKXl8G-OsqOmUaYHLVlTL1oV3rehFzcTxJ6HdtQqLxhgXBUNYGZ1Bj3fhbduMZhTvRszUz5aVDIvoR9Eu7NSqb0dhOmVc8hQnW2n478MX3_OT6uPFv4u-gbvD4zwrssPRj5dwjyJoqtOBd6FzOV_6V3DbrVDF89fN9r4G-67-ZA
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3daxNBEB9qK8UX67exVVfxwZezl_243QVfamtsNQlBTOnbsZ8Q0aQkTcD_3tm7y4VSBcG3g5tll52dmd_dzPwW4I330YuYWre0lRkvlMlsLkJGCxu70WNIrEr-z_tyOFQXF3q0Be_XvTA1P0T7wy1ZRuWvk4GHSx8PN6yh33-u3lGtuvIW7HChCzTLnZOvvXG_9cRK11kE9AYZxiGxZhbK6WE7-Ho8ugEyr2PWKuj09v5vuffgbgM2yVF9Ou7DVpg-gN1Bk05_CGG0aRsgG95vMosEcSEZHH3qjwdn5DSksuuryYJ8IKvJfLkgi-U8GhyDaklsnsQl2gF0c6mG3iVfQSap72SGyNz8egTj3sdvx6dZc-9C5phgMrWo5ZYzFpgTTmgWnVNWWkOlVZYKQzHcWWW8EToImZs8cvwMU8pzq1QsLHsM29PZNDwFElzwUgoXlNccla-MQat3xtlAQyF0B96ud790DSl5uhvjR1nTKdMSt62stq0Dr1vRy5qJ409CB2sVlo0xLkqGsDI5gy7vwKv2NZpRyo2YaZgtKxmW0I-iHXhSq76dhemccclzXGyl4b9PX34enFcPz_5d9CXsjk56Zf9s-GUf7lDETHU18AFsX82X4TncdivU8PxFc7p_A4oU_d8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Performance+evaluation+of+the+MAGLUMI+Hepatitis+B+virus+surface+antigen+chemiluminescence+immunoassay&rft.jtitle=Journal+of+medical+virology&rft.au=Shen%2C+Lihong&rft.au=Zhang%2C+Yun&rft.au=Shi%2C+Min&rft.au=Shao%2C+Lijia&rft.date=2024-07-01&rft.issn=1096-9071&rft.eissn=1096-9071&rft.volume=96&rft.issue=7&rft.spage=e29817&rft_id=info:doi/10.1002%2Fjmv.29817&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon